Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2026
Hemab Therapeutics receives FDA breakthrough therapy designation for sutacimig in Glanzmann thrombasthenia
5 March 2026 - Sutacimig has potential to become a first in class prophylactic treatment for Glanzmann thrombasthenia, an inherited serious ...
Posted by Michael Wonder on 27 Feb 2026
Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome
26 February 2026 - Breakthrough therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multi-domain ...
Posted by Michael Wonder on 21 Feb 2026
Vanda Pharmaceuticals announces FDA approval of Bysanti (milsaperidone) for the treatment of bipolar I disorder and schizophrenia - a new chemical entity opening new horizons in psychiatric innovation
20 February 2026 - - Vanda Pharmaceuticals today announced that the US FDA has approved Bysanti (milsaperidone) tablets, a first ...
Posted by Michael Wonder on 29 Jan 2026
CMS announces selection of drugs for third cycle of Medicare drug price negotiation program, including first ever Part B drugs
27 January 2026 - The Centers for Medicare & Medicaid Services announced the selection of 15 high cost prescription drugs covered ...
Posted by Michael Wonder on 17 Nov 2025
Business Council urges unlocking ‘Aladdin's cave’ of Medicare data to save lives, health system
17 November 2025 - Unlocking an “Aladdin’s cave” of Medicare data is the key to saving Australia’s celebrated health system ...
Posted by Michael Wonder on 04 Jun 2025
DoH publishes revised agenda for May 2025 PBAC meeting in June!
4 June 2025 - The DoH has published a revised agenda for last month's PBAC meeting. ...
Posted by Michael Wonder on 05 Apr 2025
Trump Administration rejects expanding Medicare, Medicaid coverage of obesity drugs
4 April 2025 - Biden Administration had proposed late last year coverage of the popular medicines for obesity. ...
Posted by Michael Wonder on 17 Feb 2025
Cost sharing for preferred branded drugs in Medicare Part D
14 February 2025 - Most individuals in the US are concerned about prescription drug affordability. ...
Posted by Michael Wonder on 02 Feb 2025
Cell and gene therapies - improving access and outcomes for Medicare and Medicaid beneficiaries
1 February 2025 - State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements ...
Posted by Michael Wonder on 19 Jan 2025
Ozempic among the next drugs up for Medicare price negotiations
17 January 2025 - List of drugs account for $41 billion in annual Medicare spending, Biden administration says. ...
Posted by Michael Wonder on 24 Dec 2024
HHS announces cost savings for 64 prescription drugs thanks to the Medicare Prescription Drug Inflation Rebate Program established by the Biden-Harris Administration’s lower cost prescription drug law
20 December 2024 - Under the Inflation Reduction Act, some people with Medicare will pay less for some Part B ...
Posted by Michael Wonder on 07 Dec 2024
Biden-Harris Administration takes next steps to increase access to sickle cell disease treatments
4 December 2024 - Today, the Biden-Harris Administration announced that two drug manufacturers with FDA approved gene therapies for sickle ...
Posted by Michael Wonder on 04 Dec 2024
Biden-Harris Administration announces Medicare Advantage and Medicare Part D prescription drug proposals that aim to improve care and access for enrollees
26 November 2024 - Today, the CMS is proposing actions in the Medicare Advantage and Medicare Part D prescription drug programs ...
Posted by Michael Wonder on 15 Nov 2024
Representativeness of studies required under Medicare’s coverage with evidence development program
13 November 2024 - Medicare beneficiaries are often inadequately represented in clinical studies supporting US Food and Drug Administration medical product ...
Posted by Michael Wonder on 13 Nov 2024
The sickest patients are fleeing private Medicare plans costing taxpayers billions
11 November 2024 - Medicare Advantage patients in the last year of life were far more likely to switch to traditional ...